Vaishali Pharma Intrinsic Value
Vaishali Pharma intrinsic value. Vaishali Pharma (VAISHALI) median intrinsic value is ₹8.46 from 8 valuation models (range ₹2–₹20), vs current price ₹8.17 — +3.5% upside (Trading Near Calculated Value), margin of safety 3.4%. Read VAISHALI dividend payout details for the complete payout history and dividend yield track record.
VAISHALI Valuation Methods Summary — DCF, Graham Number & P/E
Vaishali Pharma intrinsic value across 8 models vs current price ₹8.17 — upside/downside and value range per method. For current market price and key ratios, visit VAISHALI stock price BSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹2.64 | ₹2.11 - ₹3.17 | -67.7% | EPS: ₹0.12, Sector P/E: 22x |
| Book Value Method | asset | ₹20.43 | ₹18.39 - ₹22.47 | +150.1% | Book Value/Share: ₹26.54, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹16.34 | ₹14.71 - ₹17.97 | +100.0% | Revenue/Share: ₹43.08, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹15.38 | ₹13.84 - ₹16.92 | +88.2% | EBITDA: ₹4.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹3.57 | ₹2.86 - ₹4.28 | -56.3% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹2.45 | ₹2.21 - ₹2.70 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹2.45 | ₹2.21 - ₹2.70 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹8.46 | ₹7.61 - ₹9.31 | +3.5% | EPS: ₹0.12, BVPS: ₹26.54 |
VAISHALI Intrinsic Value vs Market Price — All Valuation Models
Vaishali Pharma fair value range ₹2–₹20 vs current market price ₹8.17 across 8 valuation models. Compare with VAISHALI fundamental valuation to assess whether the stock is under or overvalued.
VAISHALI Intrinsic Value Analysis — Undervalued or Overvalued?
Vaishali Pharma median intrinsic value ₹8.46, current price ₹8.17 — Trading Near Calculated Value by 3.5%, margin of safety 3.4%.
What is the intrinsic value of VAISHALI?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Vaishali Pharma (VAISHALI) is ₹8.46 (median value). With the current market price of ₹8.17, this represents a +3.5% variance from our estimated fair value.
The valuation range spans from ₹2.45 to ₹20.43, indicating ₹2.45 - ₹20.43.
Is VAISHALI undervalued or overvalued?
Based on our multi-method analysis, Vaishali Pharma (VAISHALI) appears to be trading near calculated value by approximately 3.5%.
VAISHALI Financial Health — Key Ratios vs Industry Benchmarks
Vaishali Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 18.83 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Operating Margin | -1.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.91x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
VAISHALI Cash Flow Quality — Operating & Free Cash Flow
Vaishali Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹0 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2025 | ₹-18 Cr | ₹-18 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |